Key nutrients missing: Half of menopause supplements studied lacked vitamin D and less than a quarter contained calcium, despite both being recommended for bone health.
Potential health hazards: Some products contain black cohosh, linked to liver toxicity, or excessive vitamin D, which can cause vomiting, confusion and organ damage.
Call for regulation: Researchers urge clinical trials and tighter oversight to curb misinformation and protect women from ineffective or harmful products.
UCL study flags safety risks in popular menopause supplements
University College London researchers analysed 201 menopause supplements from nine UK retailers, revealing wide variation in ingredients, doses and prices. Half lacked vitamin D and only 23.9% contained calcium, both recommended by menopause societies for bone health. Many products instead featured herbs, vitamins and phytoestrogens, with some botanicals such as black cohosh carrying known risks of liver toxicity, and excessive vitamin D intake posing potential for harmful calcium imbalances.
Ingredient Type
Prevalence in Products
Common Examples
Potential Health Risks
Herbs
80%
Red clover, Sage
Some may carry liver toxicity (e.g., black cohosh)
Vitamins
77%
Vitamin B6
Excessive intake can cause high calcium levels, vomiting, confusion
Phytooestrogens
74%
Soy derivatives, Red clover
May affect hormone-sensitive conditions
Vitamin D
50%
Vitamin D3
Excessive intake can lead to high calcium levels and organ damage
Calcium
23.9%
Calcium carbonate
Deficiency may affect bone health; excessive intake can cause adverse effects.
Why these findings matter for millions of women
Around 13 million women in the UK are perimenopausal or menopausal, with about 80% experiencing symptoms like hot flushes, brain fog and mood changes. While hormone replacement therapy is the main treatment, many turn to supplements for relief, often influenced by marketing that is not backed by scientific evidence. The study warns that misinformation and high prices—up to £95 a month—could lead women to spend substantially on products with unproven benefits and possible health risks.
Experts warn of 'menopause gold rush' fuelled by misinformation
Lead author Professor Joyce Harper described a 'menopause gold rush', with companies targeting mid‑life women and influencers promoting products without scientific backing. This trend risks spreading misinformation and diverting consumers from evidence‑based care. Experts note many active ingredients in menopause supplements are available in cheaper general multivitamins or herbal products, and that a balanced diet may provide similar nutritional benefits without the risks. The Independent +4
Recent cases and regulatory alerts highlight ongoing risks
Case reports, such as a suspected supplement‑induced eosinophilic ascites, and regulatory advisories on botanicals like ashwagandha and black cohosh, illustrate real‑world health risks. These range from rare but severe liver injury to gastrointestinal symptoms and potential drug interactions. Authorities advise stopping use and seeking medical attention if symptoms like jaundice, dark urine or unusual fatigue occur, underscoring the need for consumer vigilance and professional guidance.
Supplement
Reported Adverse Event
Population/Case
Regulatory/Guidance Notes
Black cohosh
Liver toxicity, jaundice, fatigue
Multiple cases including 52- and 54-year-old women
UK packaging warns to stop if liver symptoms appear; avoid in pregnancy and liver disease
Ashwagandha (Withania somnifera)
Liver injury, gastrointestinal symptoms
Reported in Australia and internationally; some hospitalizations
TGA advises stopping use if symptoms occur; very rare risk
Soy isoflavones
Abnormal uterine bleeding, uterine lining changes
High-dose intake (>40g/day) in postmenopausal women
Caution in hormone-sensitive conditions; moderate dietary intake considered safe
St. John’s Wort
Serotonin syndrome, drug interactions, dizziness
Included in some menopause formulas
Can interact with tamoxifen, blood thinners, contraceptives; monitor closely
Red ginseng
Vaginal bleeding
Postmenopausal women in clinical studies
Monitor for unexpected bleeding; evaluate for serious conditions.